Association Between Inflammatory Biomarkers and the Cognitive Response to a Multidomain Intervention: Secondary Longitudinal Analyses from the MAPT Study

Overview

Journal Geroscience

Date 2025 Jan 17

PMID 39825168

Authors

Emmanuel Gonzalez-Bautista

Maria Soto

Gabor Abellan Van Kan

Julien Delrieu

Affiliations

Soon will be listed here.

Abstract

The aim of this study is to evaluate the association of systemic inflammation measured by plasma biomarkers with the change in cognitive function among participants from the Multidomain Alzheimer Preventive Trial (MAPT) exposed to the multidomain intervention (MI). Secondary analysis of the MAPT longitudinal data. MAPT is a randomized, placebo-controlled trial with 3 interventional groups (omega-3 only, MI only, omega-3 plus MI) and a control group. We tested the association of the change in cognitive function with inflammatory biomarkers (tumoral necrosis factor receptor-1 (TNFR1), monocyte chemoattractant protein-1 (MCP1), Growth Differentiation Factor-15 (GDF15), Interleukin-6 (IL6) and C reactive protein (CRP)) using mixed-effects models. A subgroup analysis was performed in those exposed to the MI. The response to the MI was defined as the change in the composite cognitive score over the 2-year clinical follow-up period. by modeling the response to the intervention and identifying "good responders", i.e., those in the 5th quintile of response at the end of the intervention period (2 years after the measurement of inflammatory markers). We included 1,527 participants (mean age 75.3, SD = 4.4; 64% female). Higher levels of GDF15 and TNFR1 were associated with a worse trajectory in the cognitive composite score in adjusted models. "Good responders" had an estimated mean change in the composite score of 0.051 (SD 0.062) over two years of intervention, compared to -0.136 (SD = 0.111) for the "not-good responders". Higher IL6 levels were associated with a decreased likelihood of being a "good responder" (OR = 0.22, p = 0.018, 95% CI 0.06; 0.78), with similar results for CRP (OR = 0.48, p = 0.009, 95% CI 0.28; 0.84). Higher inflammation was associated with a worse cognitive trajectory among nondemented participants and a lower likelihood of being classified as a "good responder" in those receiving a MI. Further confirmation of these findings could lead to the use of systemic inflammation as inclusion or stratification criteria in prevention trials.

References

Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R . A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015; 385(9984):2255-63. DOI: 10.1016/S0140-6736(15)60461-5. View

Andrieu S, Coley N, Lovestone S, Aisen P, Vellas B . Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurol. 2015; 14(9):926-944. DOI: 10.1016/S1474-4422(15)00153-2. View

Soo Lee K, Lee Y, Back J, Son S, Choi S, Chung Y . Effects of a multidomain lifestyle modification on cognitive function in older adults: an eighteen-month community-based cluster randomized controlled trial. Psychother Psychosom. 2014; 83(5):270-8. DOI: 10.1159/000360820. View

Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J . Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006; 5(9):735-41. DOI: 10.1016/S1474-4422(06)70537-3. View

van Dalen J, Moll van Charante E, Caan M, Scheltens P, Majoie C, Nederveen A . Effect of Long-Term Vascular Care on Progression of Cerebrovascular Lesions: Magnetic Resonance Imaging Substudy of the PreDIVA Trial (Prevention of Dementia by Intensive Vascular Care). Stroke. 2017; 48(7):1842-1848. DOI: 10.1161/STROKEAHA.117.017207. View

Solomon A, Turunen H, Ngandu T, Peltonen M, Levalahti E, Helisalmi S . Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention: A Subgroup Analysis of a Randomized Clinical Trial. JAMA Neurol. 2018; 75(4):462-470. PMC: 5885273. DOI: 10.1001/jamaneurol.2017.4365. View

Lim A, Krajina K, Marsland A . Peripheral inflammation and cognitive aging. Mod Trends Pharmacopsychiatry. 2014; 28:175-87. DOI: 10.1159/000346362. View

Marsland A, Gianaros P, Kuan D, Sheu L, Krajina K, Manuck S . Brain morphology links systemic inflammation to cognitive function in midlife adults. Brain Behav Immun. 2015; 48:195-204. PMC: 4508197. DOI: 10.1016/j.bbi.2015.03.015. View

Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues J . MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER'S DISEASE: DESIGN AND BASELINE DATA. J Prev Alzheimers Dis. 2015; 1(1):13-22. PMC: 4652787. View

10.

Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S . Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017; 16(5):377-389. DOI: 10.1016/S1474-4422(17)30040-6. View

11.

Grober E, Sanders A, Hall C, Lipton R . Free and cued selective reminding identifies very mild dementia in primary care. Alzheimer Dis Assoc Disord. 2010; 24(3):284-90. PMC: 2929322. DOI: 10.1097/WAD.0b013e3181cfc78b. View

12.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

13.

Donohue M, Sperling R, Salmon D, Rentz D, Raman R, Thomas R . The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014; 71(8):961-70. PMC: 4439182. DOI: 10.1001/jamaneurol.2014.803. View

14.

Liu-Seifert H, Andersen S, Case M, Sparks J, Holdridge K, Wessels A . Statistical properties of continuous composite scales and implications for drug development. J Biopharm Stat. 2017; 27(6):1104-1114. DOI: 10.1080/10543406.2017.1315819. View

15.

Singh T, Newman A . Inflammatory markers in population studies of aging. Ageing Res Rev. 2010; 10(3):319-29. PMC: 3098911. DOI: 10.1016/j.arr.2010.11.002. View

16.

Sokolova A, Hill M, Rahimi F, Warden L, Halliday G, Shepherd C . Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol. 2008; 19(3):392-8. PMC: 8094842. DOI: 10.1111/j.1750-3639.2008.00188.x. View

17.

Conte M, Giuliani C, Chiariello A, Iannuzzi V, Franceschi C, Salvioli S . GDF15, an emerging key player in human aging. Ageing Res Rev. 2022; 75:101569. DOI: 10.1016/j.arr.2022.101569. View

18.

Wang D, Day E, Townsend L, Djordjevic D, Jorgensen S, Steinberg G . GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. Nat Rev Endocrinol. 2021; 17(10):592-607. DOI: 10.1038/s41574-021-00529-7. View

19.

Dedeyne L, Deschodt M, Verschueren S, Tournoy J, Gielen E . Effects of multi-domain interventions in (pre)frail elderly on frailty, functional, and cognitive status: a systematic review. Clin Interv Aging. 2017; 12():873-896. PMC: 5448695. DOI: 10.2147/CIA.S130794. View

20.

Yaffe K, Kanaya A, Lindquist K, Simonsick E, Harris T, Shorr R . The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004; 292(18):2237-42. DOI: 10.1001/jama.292.18.2237. View